Previous Page  63 / 232 Next Page
Information
Show Menu
Previous Page 63 / 232 Next Page
Page Background

Speech Outcomes After Clinically Indicated Posterior

Pharyngeal Flap Takedown

Evan B. Katzel, MD, Sameer Shakir, MD, Sanjay Naran, MD, Zoe MacIsaac, MD, Liliana Camison, MD,

Matthew Greives, MD, Jesse A. Goldstein, MD, Lorelei J. Grunwaldt, MD,

Matthew D. Ford, MS, CCC-SLP, and Joseph E. Losee, MD

Background:

Velopharyngeal insufficiency affects as many as one in three pa-

tients after cleft palate repair. Correction using a posterior pharyngeal flap

(PPF) has been shown to improve clinical speech symptomatology; however, PPFs

can be complicated by hyponasality and obstructive sleep apnea. The goal of this study

was to assess if speech outcomes revert after clinically indicated PPF takedown.

Methods:

The cleft-craniofacial database of the Children's Hospital of Pittsburgh

at the University of Pittsburgh Medical Center was retrospectively queried to identify

patients with a diagnosis of velopharyngeal insufficiency treated with PPF who

ultimately required takedown. Using the Pittsburgh Weighted Speech Score (PWSS),

preoperative scores were compared to those after PPF takedown. Outcomes

after 2 different methods of PPF takedown (PPF takedown alone or PPF takedown

with conversion to Furlow palatoplasty) were stratified and cross-compared.

Results:

A total of 64 patients underwent takedown of their PPF. Of these,

18 patients underwent PPF takedown alone, and 46 patients underwent PPF

takedown with conversion to Furlow Palatoplasty. Patients averaged 12.43

(range, 3.0

22.0)(SD: 3.93) years of age at the time of PPF takedown, and

58% were men. Demographics between groups were not statistically different.

The mean duration of follow-up after surgery was 38.09 (range, 1

104) (SD,

27.81) months. For patients undergoing PPF takedown alone, the mean preoper-

ative and postoperative PWSS was 3.83 (range, 0.0

23.0) (SD, 6.13) and 4.11

(range, 0.0

23.0) (SD, 5.31), respectively (

P

= 0.89). The mean change in PWSS

was 0.28 (range,

9.0 to 7.0) (SD, 4.3). For patients undergoing takedown of PPF

with conversion to Furlow palatoplasty, the mean preoperative and postoperative

PWSS was 6.37 (range, 0

26) (SD, 6.70) and 3.11 (range, 0.0

27.0) (SD, 4.14),

respectively (

P

< 0.01). The mean change in PWSS was

3.26 (range,

23.0 to

4.0) (SD, 4.3). For all patients, the mean preoperative PWSS was 5.66 (range,

0.0

26) (SD, 6.60) and 3.39 (range, 0.0

27) (SD, 4.48), respectively (

P

< 0.05).

The mean change in PWSS was

2.26 (range,

23.0 to 7) (SD, 5.7). There was no

statistically significant regression in PWSS for either surgical intervention. Two

patients in the PPF takedown alone cohort demonstrated deterioration in PWSS

that warranted delayed conversion to Furlow palatoplasty. Approximately 90%

of patients, who undergo clinically indicated PPF takedown alone, without

conversion to Furlow Palatoplasty, will show no clinically significant reduction

in speech.

Conclusions:

Although there is concern that PPF takedown may degrade speech,

this study finds that surgical takedown of PPF, when clinically indicated, does

not result in a clinically significant regression of speech.

Key Words:

cleft lip, cleft palate, velopharnygeal insufficiency, sleep apnea,

craniofacial, Furlow plasty, pharyngoplasty, double opposing z-plasty, VPI

(

Ann Plast Surg

2016;77: 420

424)

T

he velopharyngeal valve separates the oral and nasal pharynx

during swallowing and speaking. It is created by the lateral pharyn-

geal walls, the posterior pharyngeal wall, and the velum, and selectively

allows and resists airflow during normal speech production. Velo-

pharyngeal insufficiency (VPI) is the inability to completely occlude

the velopharyngeal port during speech and can be an unfortunate

complication seen in approximately 30% of palatal surgery.

1

Data sug-

gest that straightline palatoplasty without intravelar veloplasty or with

incomplete intravelar veloplasty place patients at a greater risk for

VPI.

2

Sphincterplasty, fat grafting, or filler injection to the posterior

pharynx and/or obturators can be used to treat VPI; however, the gold

standard treatment of VPI after cleft palate repair is pharyngoplasty,

and the posterior pharyngeal flap (PPF) is one of the most frequently

performed procedures.

The PPF was initially described for the treatment of VPI in 1865

by Passavant.

3

Creation of a PPF is often used to treat VPI and is well

established to improve clinical speech symptomatology.

4

7

Long-term

success rates with PPF range from 74% to 98%.

1,8

11

However, PPFs

are accompanied by the potential morbidity of hyponasality and postop-

erative obstructive sleep apnea (OSA), with OSA reported in as many

as 40% of the cases.

12,13

Although, a large body of literature exists re-

garding the identification, prevention, and management of OSA in this

population, studies have yet to answer whether speech symptomatology

suffers as a consequence of PPF takedown.

8,14

19

There is also a lack

of literature exploring conversion of previous straightline palatoplasties

to Furlow palatoplasty for these patients. The treatment of these patients

is controversial, given the challenge of treating the OSA

caused by

the PPF

while maintaining the improvement in speech

owed to the

PPF

. Given the lack of existing literature, the study aims to assess

speech outcomes after clinically indicated PPF takedown alone or when

performed with conversion to Furlow palatoplasty. This study hypothe-

sizes that PPF takedown or PPF takedown with conversion to Furlow

palatoplasty can be performed for the treatment of OSAwithout delete-

rious effects on speech outcomes.

METHODS

The study was approved by the Institutional Review Board at the

University of Pittsburgh Medical Center. The Cleft-Craniofacial Data-

base of the Children's Hospital of Pittsburgh of University of Pittsburgh

Medical Center was queried from 1992 to 2012 to identify patients

with a diagnosis of VPI treated with PPF and eventual PPF takedown.

All patients who fit these criteria were included in this study. No pa-

tients who had a diagnosis of VPI treated with PPF and eventual PPF

takedown were excluded. Demographic, operative, and speech data

were stratified based on treatment modality (ie, PPF takedown alone

versus PPF takedown with conversion to Furlow palatoplasty) and

compared. Demographic data included sex and age at time of PPF take-

down. Operative data included surgical complications and postopera-

tive length of follow-up.

The PittsburghWeighted Speech Score (PWSS) was used to quan-

tify preoperative and postoperative speech changes. The PWSS is a vali-

dated measure of clinical speech outcomes that rates 5 components of

Received April 16, 2015, and accepted for publication, after revision July 27, 2015.

From the Division of Pediatric Plastic Surgery, Children's Hospital of Pittsburgh,

University of Pittsburgh Medical Center, Pittsburgh, PA.

Conflicts of interest and sources of funding: none declared.

Reprints: Evan B. Katzel, MD, Division of Pediatric Plastic Surgery, Children's

Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA.

E-mail:

katzeleb@upmc.edu.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0148-7043/16/7704

0420

DOI: 10.1097/SAP.0000000000000632

H

EAD AND

N

ECK

S

URGERY

www.annalsplasticsurgery.com

Annals of Plastic Surgery

Volume 77, Number 4, October 2016

Reprinted by permission of Ann Plast Surg. 2016; 77(4):420-424.

41